Literature DB >> 7909438

Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.

J Bertram1, M Killian, W Brysch, K H Schlingensiepen, M Kneba.   

Abstract

A considerable reduction of up to 75% at the protein level of the erbB2 gene product was observed using phosphorothioate antisense oligonucleotides directed against specific sequences of the erbB2 mRNA. Antisense oligonucleotides used were the 14-mer (translation start region) and the 17-mer (3' translated region) all-phosphorothioate oligonucleotides (S-ODNs). Sense or random sequences were used as a control. The greatest reduction at the erbB2 protein level was obtained after a 24h incubation with a single dose of 2 microM antisense S-ODN. The erbB2-mRNA-specific and the tyrosine kinase consensus antisense S-ODNs were comparably effective in inhibiting erbB2 expression. Addition of the transfection reagent DOTAP diminished the efficiency of erbB2 protein reduction by antisense S-ODNs after an incubation period of 24h but was more effective after 48h compared to the application of antisense S-ODNs alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909438     DOI: 10.1006/bbrc.1994.1499

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line.

Authors:  Yong He; Jun Zhou; Jin-Sheng Wu; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

Authors:  Timo Faltus; Juping Yuan; Brigitte Zimmer; Andrea Krämer; Sibylle Loibl; Manfred Kaufmann; Klaus Strebhardt
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA.

Authors:  Bishnuhari Paudyal; Kaijun Zhang; Chang-Po Chen; Matthew E Wampole; Neil Mehta; Edith P Mitchell; Brian D Gray; Jeffrey A Mattis; Koon Y Pak; Mathew L Thakur; Eric Wickstrom
Journal:  Nucl Med Biol       Date:  2013-09-24       Impact factor: 2.408

4.  Targeted tumor killing via an intracellular antibody against erbB-2.

Authors:  J Deshane; G P Siegal; R D Alvarez; M H Wang; M Feng; G Cabrera; T Liu; M Kay; D T Curiel
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 5.  Gene therapy for carcinoma of the breast: Genetic ablation strategies.

Authors:  D T Curiel
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

6.  HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

Authors:  Masaki Fujimura; Noriyuki Katsumata; Hiroshi Tsuda; Naoko Uchi; Satomi Miyazaki; Takao Hidaka; Masatoshi Sakai; Shigeru Saito
Journal:  Jpn J Cancer Res       Date:  2002-11

7.  Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma.

Authors:  D P Hollywood; H C Hurst
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

8.  SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression.

Authors:  C Allal; S Sixou; R Kravtzoff; N Soulet; G Soula; G Favre
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.